ATRC News and Press, AtriCure Inc. From 07/12/22

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2022 financial results on...

AtriCure presents with numerous inflection points that sit on the distant horizon. However, data from its operating performance suggests it has to overcome numerous idiosyncratic headwinds. The company has printed a series of operating, net and FCF losses in the years to date. ...

Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effec...

AtriCure Inc. (ATRC) Q1 2022 Results Conference Call May 3, 2022 04:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants Robbie Marcus - JPMorgan Danielle Antalffy - SVB Leerink John McAulay - Stifel Sam ...

AtriCure press release (NASDAQ:ATRC): Q1 Non-GAAP EPS of -$0.33 beats by $0.01. Revenue of $74.58M beats by $3.41M. For FY22 revenue is projected to be ~$318M-330M, Non-GAAP EPS of ~$1.07-1.12 For further details see: AtriCure Non-GAAP EPS of -$0.33 beats by $0.01, revenue of $74.58M be...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. “Our team deliver...

New clamp is designed to improve efficiency of concomitant ablation procedures AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, t...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2022 financial results on ...

AtriCure Inc. (ATRC) Q4 2021 Results Conference Call February 15, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants David Saxon - Needham Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler...